ClinicalTrials.Veeva

Menu
H

Hospital Moinhos de Vento | Oncology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
ABX464
BIIB059
SAR441344
RO7790121
Frexalimab
Deucravacitinib
Bevacizumab
Fulvestrant
Litifilimab

Parent organization

This site is a part of Hospital Moinhos de Vento

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

40 of 43 total trials

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: Litifilimab
Drug: Placebo

Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced...

Enrolling
Renal Cell Carcinoma
Drug: Belzutifan
Drug: Zanzalintinib

The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participa...

Enrolling
Metastasis
Castration-Resistant Prostatic Cancer
Drug: Rescue Medication
Drug: MK-5684

Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metas...

Enrolling
Bladder Cancer
Drug: Rescue medications for chemotherapy
Drug: Rescue medications for sacituzumab tirumotecan

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Active, not recruiting
Crohn's Disease
Drug: Mirikizumab

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in...

Enrolling
Metabolic Dysfunction-Associated Steatotic Liver Disease
Drug: Tirzepatide
Drug: Placebo

This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in...

Active, not recruiting
Coeliac Disease
Celiac Disease
Dietary Supplement: SIGE
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disea...

Enrolling
Alzheimer Disease
Drug: Xanomeline Enteric Capsule
Drug: Xanomeline/Trospium Chloride Capsule

The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and ado...

Enrolling
Colitis, Ulcerative
Drug: Icotrokinra
Drug: Placebo

This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenv...

Active, not recruiting
Unresectable Hepatocellular Carcinoma
Drug: Lenvatinib
Drug: Atezolizumab

The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately t...

Enrolling
Crohn Disease
Drug: Icotrokinra
Drug: Placebo

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Active, not recruiting
Breast Neoplasms
Drug: Anastrozole
Drug: Tamoxifen

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who r...

Enrolling
Carcinoma, Non-Small-Cell Lung
Biological: Intismeran autogene
Drug: Pemetrexed

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physici...

Enrolling
Breast Neoplasms
Drug: Liposomal doxorubicin
Drug: Sacituzumab tirumotecan

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO779...

Enrolling
Moderately to Severely Active Ulcerative Colitis
Drug: Afimkibart
Drug: Placebo

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also...

Enrolling
Moderately to Severely Active Crohns Disease
Drug: Placebo
Drug: Afimkibart

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, b...

Enrolling
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)
Drug: Giredestrant

The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study...

Active, not recruiting
Ulcerative Colitis
Drug: IV Placebo
Drug: SC Placebo

The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants ag...

Enrolling
Plaque Psoriasis
Other: Placebo matching deucravacitinib
Drug: Deucravacitinib

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Lilly logo
Pfizer logo
Roche logo
Sanofi logo
Bristol-Myers Squibb (BMS) logo
A
Biogen logo
Janssen (J&J Innovative Medicine) logo
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems